159 related articles for article (PubMed ID: 3075434)
1. Pharmacodynamic evaluation of ofloxacin and trimethoprim-sulfamethoxazole in vaginal fluid of women treated for acute cystitis.
Tartaglione TA; Johnson CR; Brust P; Opheim K; Hooton TM; Stamm WE
Antimicrob Agents Chemother; 1988 Nov; 32(11):1640-3. PubMed ID: 3075434
[TBL] [Abstract][Full Text] [Related]
2. Ofloxacin versus trimethoprim-sulfamethoxazole for treatment of acute cystitis.
Hooton TM; Latham RH; Wong ES; Johnson C; Roberts PL; Stamm WE
Antimicrob Agents Chemother; 1989 Aug; 33(8):1308-12. PubMed ID: 2802557
[TBL] [Abstract][Full Text] [Related]
3. Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women.
Hooton TM; Winter C; Tiu F; Stamm WE
JAMA; 1995 Jan; 273(1):41-5. PubMed ID: 7654268
[TBL] [Abstract][Full Text] [Related]
4. Single-dose and three-day regimens of ofloxacin versus trimethoprim-sulfamethoxazole for acute cystitis in women.
Hooton TM; Johnson C; Winter C; Kuwamura L; Rogers ME; Roberts PL; Stamm WE
Antimicrob Agents Chemother; 1991 Jul; 35(7):1479-83. PubMed ID: 1929311
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for trimethoprim-sulfamethoxazole resistance in patients with acute uncomplicated cystitis.
Colgan R; Johnson JR; Kuskowski M; Gupta K
Antimicrob Agents Chemother; 2008 Mar; 52(3):846-51. PubMed ID: 18086847
[TBL] [Abstract][Full Text] [Related]
6. Effect of trimethoprim and trimethoprim-sulfamethoxazole on development of drug-resistant vaginal and fecal floras.
Pancoast SJ; Hyams DM; Neu HC
Antimicrob Agents Chemother; 1980 Feb; 17(2):263-8. PubMed ID: 7387147
[TBL] [Abstract][Full Text] [Related]
7. The diffusion and concentration of trimethoprim in human vaginal fluid.
Stamey TA; Condy M
J Infect Dis; 1975 Mar; 131(3):261-6. PubMed ID: 1092766
[TBL] [Abstract][Full Text] [Related]
8. Ofloxacin versus trimethoprim-sulphamethoxazole in acute cystitis.
Block JM; Walstad RA; Bjertnaes A; Hafstad PE; Holte M; Ottemo I; Svarva PL; Rolstad T; Peterson LE
Drugs; 1987; 34 Suppl 1():100-6. PubMed ID: 3501750
[TBL] [Abstract][Full Text] [Related]
9. [Susceptibility of gram negative bacteria to TMP-SMX and ofloxacin].
Unal S; Aydin M; Akin A
Mikrobiyol Bul; 1988; 22(4):316-21. PubMed ID: 3266971
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors for Trimethoprim and Sulfamethoxazole-Resistant Escherichia Coli in ED Patients with Urinary Tract Infections.
Wesolek JL; Wu JY; Smalley CM; Wang L; Campbell MJ
Am J Emerg Med; 2022 Jun; 56():178-182. PubMed ID: 35405469
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan.
Brown PD; Freeman A; Foxman B
Clin Infect Dis; 2002 Apr; 34(8):1061-6. PubMed ID: 11914994
[TBL] [Abstract][Full Text] [Related]
12. A randomised comparison of single-dose vs. three-day and ten-day therapy with trimethoprim-sulfamethoxazole for acute cystitis in women.
Gossius G; Vorland L
Scand J Infect Dis; 1984; 16(4):373-9. PubMed ID: 6396834
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Ciprofloxacin Urinary Tract Infection Group.
McCarty JM; Richard G; Huck W; Tucker RM; Tosiello RL; Shan M; Heyd A; Echols RM
Am J Med; 1999 Mar; 106(3):292-9. PubMed ID: 10190377
[TBL] [Abstract][Full Text] [Related]
14. Ofloxacin versus trimethoprim/sulfamethoxazole in the treatment of uncomplicated urinary tract infection.
Cox CE; Serfer HS; Mena HR; Briefer C; Childs SJ; Gordon SF; Zoller JS
Clin Ther; 1992; 14(3):446-57. PubMed ID: 1638586
[TBL] [Abstract][Full Text] [Related]
15. The comeback of trimethoprim in France.
Caron F; Wehrle V; Etienne M
Med Mal Infect; 2017 Jun; 47(4):253-260. PubMed ID: 28043762
[TBL] [Abstract][Full Text] [Related]
16. Treatment of cystitis in women with a single dose of trimethoprim-sulfamethoxazole.
Counts GW; Stamm WE; McKevitt M; Running K; Holmes KK; Turck M
Rev Infect Dis; 1982; 4(2):484-90. PubMed ID: 6981166
[TBL] [Abstract][Full Text] [Related]
17. Open randomized controlled parallel study of ofloxacin versus trimethoprim-sulfamethoxazole treatment of lower respiratory tract and urinary infections.
De Simone C; Di Fabio S; Moretti S; Tzantzoglou S; Trinchieri V; Gargiulo M
Chemotherapy; 1991; 37 Suppl 1():39-48. PubMed ID: 2049964
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis.
Talan DA; Krishnadasan A; Abrahamian FM; Stamm WE; Moran GJ;
Clin Infect Dis; 2008 Nov; 47(9):1150-8. PubMed ID: 18808361
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility of enterococci to trimethoprim and trimethoprim-sulfamethoxazole.
Crider SR; Colby SD
Antimicrob Agents Chemother; 1985 Jan; 27(1):71-5. PubMed ID: 3920958
[TBL] [Abstract][Full Text] [Related]
20. Serum and saliva concentrations of sulfamethoxazole and trimethoprim in adults and children: relation between saliva concentrations and in vitro activity against nasopharyngeal pathogens.
Kamme C; Melander A; Nilsson NI
Scand J Infect Dis; 1983; 15(1):107-13. PubMed ID: 6342125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
